Efficacy of Valacyclovir vs Acyclovir for the Prevention of Recurrent Herpes Simplex Virus Eye Disease: A Pilot Study - 21/08/11
, Giulio Modorati a, Laura Galli b, Paolo Rama a
Inquiries to Elisabetta Miserocchi, Department of Ophthalmology and Visual Sciences, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, ItalyRésumé |
Purpose |
To compare the efficacy of one-year treatment with valacyclovir vs acyclovir in preventing recurrence of the herpes simplex virus (HSV) eye disease.
Design |
Prospective, randomized, clinical trial pilot study.
Methods |
Fifty-two immunocompetent patients with a history of recurrent ocular HSV disease were treated at the Ocular Immunology Service, San Raffaele Hospital, Milan, Italy. Twenty-six patients were randomized to the valacyclovir group (one 500 mg tablet daily), and 26 patients were randomized to the acyclovir group (one 400 mg tablet twice daily). The recurrence rate of ocular HSV disease during 12 months of treatment and drug-related side effects were monitored.
Results |
Recurrence of any type of ocular HSV disease during the 12-month treatment period was 23.1% in the valacyclovir group, compared with 23.1% in the acyclovir group. No difference between the two groups was observed regarding the nature, frequency, or severity of adverse events. The most frequent adverse events were nausea and headache.
Conclusions |
One-year suppression therapy with oral valacyclovir (500 mg tablet daily) was shown to be as effective and as well tolerated as acyclovir (400 mg tablet twice daily) in reducing the rate of recurrent ocular HSV disease.
Le texte complet de cet article est disponible en PDF.Plan
Vol 144 - N° 4
P. 547 - octobre 2007 Retour au numéro
Article précédent
- Differences in Parapapillary Atrophy between Glaucomatous and Normal Eyes: The Beijing Eye Study
- Liang Xu, Yaxing Wang, Hua Yang, Jost B. Jonas
- Ocular Involvement Associated With an Epidemic Outbreak of Chikungunya Virus Infection
- Prajna Lalitha, Sivakumar Rathinam, Krishnadas Banushree, Shanmugam Maheshkumar, Rajendran Vijayakumar, Padmakar Sathe
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?